%0 Journal Article
%T Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
%A Walsh GM
%J Biologics: Targets and Therapy
%D 2013
%I Dove Medical Press
%X Garry M WalshDivision of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UKAbstract: Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil ) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.Keywords: IL-5, asthma, eosinophil
%U http://www.dovepress.com/profile-of-reslizumab-in-eosinophilic-disease-and-its-potential-in-the-a11900